CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.
SparkCures ID | 222 |
---|---|
Developed By | Cellectar Biosciences |
Generic Name | CLR 131 |
Additional Names | I-131-CLR1404 |
Treatment Classifications |
|
Tags |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
December 09, 2019
Dr. Ailawadhi's presentation highlighted results from 19 patients with relapsed/refractory multiple myeloma from Cellectar’s Phase 1 and Phase 2 CLOVER-1 trial collected prior to July 30, 2019. The data from the oral presentation support prior literature and preclinical data showing that fractionated dosing provides an enhancement of efficacy and safety while reducing adverse events.
May 14, 2019
September 27, 2019
SparkCures is working closely with Cellectar Biosciences to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners